This 70-study meta analysis concludes that the evidence is moderate to high that bisphosphonates and denosumab reduce the risk for hip, vertebral, and other fractures. The evidence is moderate to high that abaloparatide and teriparatide reduce clinical fractures and radiographic vertebral fractures, and low to moderate that SERMs reduce radiographic vertebral fractures, but not clinical fractures.

Beyond the strong recommendation for bisphosponates as initial medical therapy in postmenopausal women with osteoporosis, the updated guidelines also suggest (not recommend) denosumab as second line therapy in women, bisphosphonates for osteoporosis in men, and romosozumab in women with very high risk of fractures. For the complete updated guideline, see Pharmacologic Treatment of Primary Osteoporosis or Low Bone Mass to Prevent Fractures in Adults: A Living Clinical Guideline From the American College of Physicians.

Innovative and creative Risky Business events emphasize risk management, patient safety, and safety awareness. To enable all of their colleagues to work in a safer environment, they continuously “raise the bar” by exchanging safety ideas and experiences across industries. The integration of experiences from speakers representing a wide range of non-healthcare businesses into a coherent narrative and actionable results is a crucial component of Risky Business. In this two-hour video webinar taking place on Thursday, January 12 from 10:00 AM to noon , the panelists will talk about a wide range of topics, including systemic problems, workforce implications, community needs, and what industry experts are doing to address the situation. To address challenges of capacity and resource strain, they will examine cutting-edge digital technology and government and healthcare system collaboration.

Yes, you read that right. According to a recent study in Scientific Reports, Chlamydia pneumoniae assaults the central nervous system by traveling up via the nose canal and into the brain. When the bacteria reach the brain, they encourage the production of amyloid beta protein, which is regarded to be a defining feature of dementia and Alzheimer’s disease.

To sum up the reasons you should use caution: Quetiapine has a variety of effects, including sedation, influencing a number of central nervous system receptors. Quetiapine should only be used to treat insomnia in patients who also have co-occurring mood or schizophrenia spectrum disorders. Quetiapine is less frequently linked to extrapyramidal side effects and dystonia than many other antipsychotic medications, but it is more frequently linked to weight gain, metabolic syndrome, and QTc prolongation. Prior to beginning treatment and then on a frequent basis thereafter, measurements of body mass index, weight, blood pressure, fasting glucose, and lipid levels should be made, even at modest doses. Despite not producing euphoria, quetiapine is frequently misused to amplify or lessen the negative effects of illegal substances. For older patients, quetiapine has additional dangers.

Leukodystrophies, deficiency-related metabolic diseases, genetic and acquired toxic/metabolic causes, and mitochondrial diseases were identified as the genetic and metabolic disorders of adulthood producing spinal cord signal changes. A number of adult metabolic and genetic illnesses that cause spinal cord atrophy without signal changes have also been discovered. The classification based on spinal MRI results is also offered, along with suggestions for the diagnostic process and alternative diagnoses.